Insider Selling: GlaxoSmithKline plc (GSK) Insider Sells 66,159 Shares of Stock
GlaxoSmithKline plc (LON:GSK) insider Emma Walmsley sold 66,159 shares of the stock in a transaction on Friday, February 15th. The stock was sold at an average price of GBX 1,585 ($20.71), for a total value of £1,048,620.15 ($1,370,207.96).
Emma Walmsley also recently made the following trade(s):
- On Monday, February 18th, Emma Walmsley sold 9,053 shares of GlaxoSmithKline stock. The stock was sold at an average price of GBX 1,576 ($20.59), for a total value of £142,675.28 ($186,430.52).
- On Thursday, January 10th, Emma Walmsley bought 8 shares of GlaxoSmithKline stock. The shares were bought at an average cost of GBX 1,524 ($19.91) per share, for a total transaction of £121.92 ($159.31).
- On Tuesday, December 11th, Emma Walmsley bought 8 shares of GlaxoSmithKline stock. The shares were bought at an average cost of GBX 1,494 ($19.52) per share, for a total transaction of £119.52 ($156.17).
GlaxoSmithKline stock opened at GBX 1,551 ($20.27) on Thursday. GlaxoSmithKline plc has a 12 month low of GBX 1,235.20 ($16.14) and a 12 month high of GBX 1,724.50 ($22.53).
Several analysts have recently issued reports on GSK shares. Shore Capital lowered GlaxoSmithKline to a “hold” rating in a report on Friday, January 18th. HSBC set a GBX 1,820 ($23.78) price objective on GlaxoSmithKline and gave the company a “buy” rating in a research note on Friday, January 25th. Liberum Capital reaffirmed a “hold” rating and issued a GBX 1,510 ($19.73) price objective on shares of GlaxoSmithKline in a research note on Monday, January 21st. Deutsche Bank set a GBX 1,520 ($19.86) price objective on GlaxoSmithKline and gave the company a “neutral” rating in a research note on Thursday, December 20th. Finally, Barclays reaffirmed an “equal weight” rating on shares of GlaxoSmithKline in a research note on Tuesday, January 15th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have given a buy rating to the company. GlaxoSmithKline presently has a consensus rating of “Hold” and a consensus target price of GBX 1,520.93 ($19.87).
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
See Also: Relative Strength Index
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.